Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Net Income (2016 - 2025)

Haemonetics has reported Net Income over the past 17 years, most recently at $44.8 million for Q4 2025.

  • Quarterly results put Net Income at $44.8 million for Q4 2025, up 19.42% from a year ago — trailing twelve months through Dec 2025 was $175.5 million (up 34.88% YoY), and the annual figure for FY2025 was $167.7 million, up 42.63%.
  • Net Income for Q4 2025 was $44.8 million at Haemonetics, up from $38.7 million in the prior quarter.
  • Over the last five years, Net Income for HAE hit a ceiling of $58.0 million in Q1 2025 and a floor of -$11.0 million in Q2 2021.
  • Median Net Income over the past 5 years was $32.1 million (2022), compared with a mean of $27.5 million.
  • Biggest five-year swings in Net Income: plummeted 162.65% in 2021 and later soared 546.27% in 2022.
  • Haemonetics' Net Income stood at $14.8 million in 2021, then soared by 122.13% to $32.9 million in 2022, then fell by 5.11% to $31.2 million in 2023, then increased by 20.02% to $37.5 million in 2024, then increased by 19.42% to $44.8 million in 2025.
  • The last three reported values for Net Income were $44.8 million (Q4 2025), $38.7 million (Q3 2025), and $34.1 million (Q2 2025) per Business Quant data.